Hasdai D, Lerman A, Grill D E, Rihal C S, Holmes D R
Mayo Clinic, Rochester, Minnesota 55905, USA.
Ann Intern Med. 1999 Jan 19;130(2):108-15. doi: 10.7326/0003-4819-130-2-199901190-00004.
Percutaneous coronary revascularization frequently relieves angina in patients with ischemic heart disease and may obviate the need for antianginal medications.
To examine the use of antianginal medications after successful percutaneous coronary revascularization.
Retrospective cohort study of the Mayo Clinic PTCA [percutaneous transluminal coronary angioplasty] Registry.
Tertiary care center.
3831 patients who underwent successful percutaneous coronary revascularization from September 1979 through August 1997 and had not had myocardial infarction within the year before the intervention.
Use of antianginal medications (beta-adrenergic blockers, nitrates, and calcium-channel blockers) before the intervention, at hospital discharge, and 6 months after the intervention.
99% of patients reported improvement in their symptoms at hospital discharge. At 6 months, 87% of patients were free of myocardial infarction, coronary bypass surgery, or additional percutaneous intervention. Compared with 66% of patients before the index intervention, only 12% of patients had severe angina at 6 months and 69% were completely free of angina. Nonetheless, at 6 months, 39% of patients were receiving beta-adrenergic blockers (preprocedure proportion, 43%; P < 0.001), 36% were receiving nitrates (preprocedure proportion, 41%; P < 0.001), and 57% were receiving calcium-channel blockers (preprocedure proportion, 50%; P < 0.001). These trends persisted for patients without hypertension and those who had complete revascularization.
Successful percutaneous coronary revascularization did not substantially supplant the use of antianginal medications, which were commonly used despite the marked improvement in anginal status. This may reflect reluctance to alter therapy once symptoms of angina subside. Guidelines on continued medical therapy after percutaneous coronary revascularization are needed.
经皮冠状动脉血运重建术常常能缓解缺血性心脏病患者的心绞痛症状,并且可能无需使用抗心绞痛药物。
研究成功进行经皮冠状动脉血运重建术后抗心绞痛药物的使用情况。
对梅奥诊所经皮腔内冠状动脉成形术(PTCA)登记处进行回顾性队列研究。
三级医疗中心。
1979年9月至1997年8月间成功进行经皮冠状动脉血运重建术且在干预前一年内未发生心肌梗死的3831例患者。
干预前、出院时及干预后6个月使用抗心绞痛药物(β受体阻滞剂、硝酸盐类和钙通道阻滞剂)的情况。
99%的患者出院时症状有所改善。6个月时,87%的患者未发生心肌梗死、冠状动脉搭桥手术或再次经皮介入治疗。与首次干预前66%的患者相比,6个月时仅有12%的患者有严重心绞痛,69%的患者完全没有心绞痛。尽管如此,6个月时,39%的患者正在使用β受体阻滞剂(术前比例为43%;P<0.001),36%的患者正在使用硝酸盐类(术前比例为41%;P<0.001),57%的患者正在使用钙通道阻滞剂(术前比例为50%;P<0.001)。这些趋势在无高血压患者和完全血运重建的患者中持续存在。
成功的经皮冠状动脉血运重建术并未显著取代抗心绞痛药物的使用,尽管心绞痛状况有明显改善,但抗心绞痛药物仍被普遍使用。这可能反映出一旦心绞痛症状缓解,患者不愿改变治疗方案。需要制定经皮冠状动脉血运重建术后继续药物治疗的指南。